麻豆传媒

More responses, longer OS in subset with the highest levels of HER2 expression

Compared with simple hysterectomy, analysis shows more sexual toxicities, worse quality of life

Overall response beats historical benchmark, but misses significance target

Impressive overall response rate with avutometinib-defactinib in RAMP 201 trial

Particularly strong PFS signal seen in patients that were mismatch repair proficient

Local and regional illness remained unchanged

One in five patients experienced changes in their care plan

Trial suggests radiation therapy alone remains standard of care for pelvic-only recurrences

Still, CALLA trial findings "will inform future strategies to improve treatment," researcher says

PARP inhibitor still has value as maintenance therapy, ARIEL3 investigator says

Post-hoc data from SOLO3 show diverging results based on prior lines of therapy